1. Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy.
- Author
-
Wang, Yu-Chen, Wang, Xi, Yu, Jiaji, Ma, Feiyang, Li, Zhe, Zhou, Yang, Zeng, Samuel, Ma, Xiaoya, Li, Yan-Ruide, Neal, Adam, Huang, Jie, To, Angela, Clarke, Nicole, Memarzadeh, Sanaz, Pellegrini, Matteo, and Yang, Lili
- Subjects
T-Lymphocytes ,Cell Line ,Tumor ,Animals ,Mice ,Inbred C57BL ,Humans ,Mice ,Neoplasms ,Lymphoma ,Melanoma ,Breast Neoplasms ,Ovarian Neoplasms ,Reactive Oxygen Species ,Monoamine Oxidase ,Monoamine Oxidase Inhibitors ,Immunotherapy ,Xenograft Model Antitumor Assays ,Gene Expression Regulation ,Neoplastic ,Drug Synergism ,Female ,Kaplan-Meier Estimate ,Single-Cell Analysis ,Programmed Cell Death 1 Receptor ,RNA-Seq ,Tumor-Associated Macrophages ,Brain Disorders ,Vaccine Related ,Neurosciences ,Cancer ,5.1 Pharmaceuticals - Abstract
Targeting tumor-associated macrophages (TAMs) is a promising strategy to modify the immunosuppressive tumor microenvironment and improve cancer immunotherapy. Monoamine oxidase A (MAO-A) is an enzyme best known for its function in the brain; small molecule MAO inhibitors (MAOIs) are clinically used for treating neurological disorders. Here we observe MAO-A induction in mouse and human TAMs. MAO-A-deficient mice exhibit decreased TAM immunosuppressive functions corresponding with enhanced antitumor immunity. MAOI treatment induces TAM reprogramming and suppresses tumor growth in preclinical mouse syngeneic and human xenograft tumor models. Combining MAOI and anti-PD-1 treatments results in synergistic tumor suppression. Clinical data correlation studies associate high intratumoral MAOA expression with poor patient survival in a broad range of cancers. We further demonstrate that MAO-A promotes TAM immunosuppressive polarization via upregulating oxidative stress. Together, these data identify MAO-A as a critical regulator of TAMs and support repurposing MAOIs for TAM reprogramming to improve cancer immunotherapy.
- Published
- 2021